JP2008508252A - 前立腺癌発病予防および前立腺肥大（ｂｐｈ）の総合的症状の効果的な治療のための、化学的な予防効果を有する、中国緑茶またはその他の野菜から抽出したカテキン、さらに正確にはポリフェノールの混合物 - Google Patents
前立腺癌発病予防および前立腺肥大（ｂｐｈ）の総合的症状の効果的な治療のための、化学的な予防効果を有する、中国緑茶またはその他の野菜から抽出したカテキン、さらに正確にはポリフェノールの混合物 Download PDFInfo
- Publication number
- JP2008508252A JP2008508252A JP2007523166A JP2007523166A JP2008508252A JP 2008508252 A JP2008508252 A JP 2008508252A JP 2007523166 A JP2007523166 A JP 2007523166A JP 2007523166 A JP2007523166 A JP 2007523166A JP 2008508252 A JP2008508252 A JP 2008508252A
- Authority
- JP
- Japan
- Prior art keywords
- prostate cancer
- vegetables
- catechin
- egcg
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 24
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title claims abstract description 24
- 235000005487 catechin Nutrition 0.000 title claims description 34
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 title claims description 34
- 244000269722 Thea sinensis Species 0.000 title claims description 30
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 title claims description 27
- 229950001002 cianidanol Drugs 0.000 title claims description 23
- 235000009569 green tea Nutrition 0.000 title claims description 19
- 235000013311 vegetables Nutrition 0.000 title claims description 17
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims description 14
- 235000013824 polyphenols Nutrition 0.000 title claims description 12
- 208000024891 symptom Diseases 0.000 title claims description 8
- 239000000126 substance Substances 0.000 title claims description 4
- 230000002265 prevention Effects 0.000 title claims description 3
- 210000002307 prostate Anatomy 0.000 title description 13
- 206010020880 Hypertrophy Diseases 0.000 title description 2
- 230000008506 pathogenesis Effects 0.000 title description 2
- 230000003449 preventive effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 claims abstract description 19
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 14
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 6
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 26
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 22
- 150000001765 catechin Chemical class 0.000 claims description 13
- 230000002113 chemopreventative effect Effects 0.000 claims description 13
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 11
- 230000009286 beneficial effect Effects 0.000 claims description 10
- 241000282412 Homo Species 0.000 claims description 9
- 238000011161 development Methods 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 4
- 235000006468 Thea sinensis Nutrition 0.000 claims description 4
- 240000006365 Vitis vinifera Species 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 claims description 2
- 229930013915 (+)-catechin Natural products 0.000 claims description 2
- 235000007219 (+)-catechin Nutrition 0.000 claims description 2
- 229930013884 (+)-gallocatechin Natural products 0.000 claims description 2
- 235000007243 (+)-gallocatechin Nutrition 0.000 claims description 2
- 229930013783 (-)-epicatechin Natural products 0.000 claims description 2
- 235000007355 (-)-epicatechin Nutrition 0.000 claims description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims description 2
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 230000001632 homeopathic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 235000008216 herbs Nutrition 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 9
- 230000002411 adverse Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000009885 systemic effect Effects 0.000 abstract 2
- 206010013990 dysuria Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 8
- 235000013616 tea Nutrition 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 238000007910 systemic administration Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000011987 flavanols Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000013188 needle biopsy Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 150000002206 flavan-3-ols Chemical class 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000064 prostate epithelial cell Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- WMBWREPUVVBILR-NQIIRXRSSA-N (-)-gallocatechin gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-NQIIRXRSSA-N 0.000 description 1
- PBZMVAYHJDFHIR-UHFFFAOYSA-N 2-phenyl-3,4-dihydrochromene-2,3-diol Chemical class OC1CC2=CC=CC=C2OC1(O)C1=CC=CC=C1 PBZMVAYHJDFHIR-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- -1 hydroxide anions Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229940081857 plasma protein fraction Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 208000026455 prostate symptom Diseases 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITBZ20040037 ITBZ20040037A1 (it) | 2004-07-27 | 2004-07-27 | Miscela di catechine ovvero polifenoli estratti dal te' verde cinese o da altri vegetali con efficacia chemiopreventiva per la prevenzione dell'insorgenza del cancro prostatico. |
| ITBZ20050004 ITBZ20050004A1 (it) | 2005-02-16 | 2005-02-16 | Miscela di catechine ovvero polifenoli estratti dal Te' Verde cinese (o da altri vegetali) Efficacia chemiopreventiva per la prevenzione dell'insorgenza del cancro prostatico e per il trattamento efficace della sintomatologia dell'ipertrofia prostati |
| PCT/IB2005/002107 WO2006013420A2 (en) | 2004-07-27 | 2005-07-21 | Mixture of catechins or rather polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy (bph) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012156634A Division JP2012236834A (ja) | 2004-07-27 | 2012-07-12 | 前立腺癌の予防および前立腺肥大（ｂｐｈ）の処置のための中国緑茶またはその他の野菜から抽出したカテキン、さらに正確にはポリフェノールの混合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508252A true JP2008508252A (ja) | 2008-03-21 |
| JP2008508252A5 JP2008508252A5 (https=) | 2012-09-06 |
Family
ID=35447932
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007523166A Pending JP2008508252A (ja) | 2004-07-27 | 2005-07-21 | 前立腺癌発病予防および前立腺肥大（ｂｐｈ）の総合的症状の効果的な治療のための、化学的な予防効果を有する、中国緑茶またはその他の野菜から抽出したカテキン、さらに正確にはポリフェノールの混合物 |
| JP2012156634A Pending JP2012236834A (ja) | 2004-07-27 | 2012-07-12 | 前立腺癌の予防および前立腺肥大（ｂｐｈ）の処置のための中国緑茶またはその他の野菜から抽出したカテキン、さらに正確にはポリフェノールの混合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012156634A Pending JP2012236834A (ja) | 2004-07-27 | 2012-07-12 | 前立腺癌の予防および前立腺肥大（ｂｐｈ）の処置のための中国緑茶またはその他の野菜から抽出したカテキン、さらに正確にはポリフェノールの混合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8044095B2 (https=) |
| EP (1) | EP1781375B1 (https=) |
| JP (2) | JP2008508252A (https=) |
| CA (1) | CA2612149C (https=) |
| ES (1) | ES2427170T3 (https=) |
| PL (1) | PL1781375T3 (https=) |
| WO (1) | WO2006013420A2 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013081046A1 (ja) * | 2011-11-29 | 2013-06-06 | 国立大学法人信州大学 | ブドウ梗由来抽出物 |
| JP2015523370A (ja) * | 2012-07-12 | 2015-08-13 | 淮北▲分▼▲昆▼健康咨▲詢▼服▲務▼有限公司Huaibei Fenkun Health Consultancy Services Co., Ltd | フェノール及びキノンを用いた腫瘍溶解及びがん細胞改造の治療法 |
| JP2016508958A (ja) * | 2012-10-15 | 2016-03-24 | ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． | 健康を促進するための緑茶抽出物と紅茶抽出物との混合物 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009053857A2 (en) * | 2007-10-26 | 2009-04-30 | Csir | Management and treatment of benign prostatic hyperplasia |
| FR2930443B1 (fr) | 2008-04-29 | 2010-06-25 | Oreal | Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12 |
| PL2348838T3 (pl) * | 2008-10-20 | 2013-10-31 | Unilever Nv | Antybakteryjna kompozycja |
| EA019746B1 (ru) | 2009-09-24 | 2014-05-30 | Юнилевер Нв | Противомикробная композиция, содержащая эвгенол, терпинеол и тимол, и способ дезинфицирования поверхности |
| US9408870B2 (en) | 2010-12-07 | 2016-08-09 | Conopco, Inc. | Oral care composition |
| WO2013064360A2 (en) | 2011-11-03 | 2013-05-10 | Unilever N.V. | A personal cleaning composition |
| BR112014012497A2 (pt) * | 2011-11-25 | 2017-06-06 | Unilever Nv | composição de cuidados orais, método de desinfetar a cavidade oral e uso |
| KR101492713B1 (ko) * | 2013-05-06 | 2015-02-12 | 대구한의대학교산학협력단 | 미숙 떫은 감의 분획물을 이용한 전립선 비대증 예방 또는 치료용 조성물 |
| KR20200074950A (ko) | 2017-10-19 | 2020-06-25 | 예일 유니버시티 | 약초 추출물 및 이의 조성물에 의한 안드로겐 수용체의 억제 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266977A (en) * | 1991-07-12 | 1993-11-30 | Linden Harry A | Lens device and method |
| US5585871A (en) * | 1995-05-26 | 1996-12-17 | Linden; Harry | Multi-function display apparatus |
| US6696484B2 (en) * | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| DE19842858A1 (de) * | 1998-09-18 | 2000-03-30 | Vollbrecht H Ruediger | Entkoffeinierung von Tee |
| KR100319973B1 (ko) | 1998-12-05 | 2002-04-22 | 이인수 | 녹차카테킨을 유효성분으로 하는 자궁경부 상피내종양 예방 또는 치료제 조성물 |
| US6410061B1 (en) * | 1999-03-30 | 2002-06-25 | Purdue Research Foundation | Tea catechins as cancer specific proliferation inhibitors |
| US6410052B1 (en) * | 1999-03-30 | 2002-06-25 | Purdue Research Foundation | Tea catechins in sustained release formulations as cancer specific proliferation inhibitors |
| US6431705B1 (en) * | 1999-11-10 | 2002-08-13 | Infoeye | Eyewear heart rate monitor |
| AU2002254007B2 (en) * | 2001-02-22 | 2006-09-21 | Purdue Research Foundation | Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer |
| WO2002067965A1 (en) | 2001-02-22 | 2002-09-06 | Purdue Research Foundation | Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer |
-
2005
- 2005-07-21 US US11/658,614 patent/US8044095B2/en active Active
- 2005-07-21 CA CA2612149A patent/CA2612149C/en not_active Expired - Lifetime
- 2005-07-21 EP EP05768182.7A patent/EP1781375B1/en not_active Expired - Lifetime
- 2005-07-21 JP JP2007523166A patent/JP2008508252A/ja active Pending
- 2005-07-21 WO PCT/IB2005/002107 patent/WO2006013420A2/en not_active Ceased
- 2005-07-21 PL PL05768182T patent/PL1781375T3/pl unknown
- 2005-07-21 ES ES05768182T patent/ES2427170T3/es not_active Expired - Lifetime
-
2012
- 2012-07-12 JP JP2012156634A patent/JP2012236834A/ja active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013081046A1 (ja) * | 2011-11-29 | 2013-06-06 | 国立大学法人信州大学 | ブドウ梗由来抽出物 |
| JP2015523370A (ja) * | 2012-07-12 | 2015-08-13 | 淮北▲分▼▲昆▼健康咨▲詢▼服▲務▼有限公司Huaibei Fenkun Health Consultancy Services Co., Ltd | フェノール及びキノンを用いた腫瘍溶解及びがん細胞改造の治療法 |
| JP2016508958A (ja) * | 2012-10-15 | 2016-03-24 | ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． | 健康を促進するための緑茶抽出物と紅茶抽出物との混合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006013420A2 (en) | 2006-02-09 |
| US20080194675A1 (en) | 2008-08-14 |
| WO2006013420B1 (en) | 2006-06-08 |
| ES2427170T3 (es) | 2013-10-29 |
| PL1781375T3 (pl) | 2013-11-29 |
| EP1781375A2 (en) | 2007-05-09 |
| WO2006013420A3 (en) | 2006-04-20 |
| CA2612149C (en) | 2015-11-10 |
| EP1781375B1 (en) | 2013-06-19 |
| JP2012236834A (ja) | 2012-12-06 |
| CA2612149A1 (en) | 2006-02-09 |
| US8044095B2 (en) | 2011-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012236834A (ja) | 前立腺癌の予防および前立腺肥大（ｂｐｈ）の処置のための中国緑茶またはその他の野菜から抽出したカテキン、さらに正確にはポリフェノールの混合物 | |
| Shwter et al. | Chemoprevention of colonic aberrant crypt foci by Gynura procumbens in rats | |
| Khalil et al. | Moringa oleifera leaves ethanolic extract influences DNA damage signaling pathways to protect liver tissue from cobalt-triggered apoptosis in rats | |
| WO2014200350A1 (en) | Composition for the treatment of neurobehavioral disorders | |
| JP2019537628A (ja) | 併用療法 | |
| Daniel et al. | In vivo antidiabetic and antioxidant activities of chloroform fraction of Nelsonia canescens Leaf in Alloxan-induced Diabetic Rats | |
| Rohdewald | Update on the clinical pharmacology of Pycnogenol (R) | |
| KR101511364B1 (ko) | 복합 생약재를 이용한 비만 및 대사증후군의 예방 또는치료용 조성물 | |
| US11090346B2 (en) | Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery | |
| EP2934561B1 (en) | Composition comprising raphanus, theobroma and passiflora for treating opioid and alcohol abuse | |
| KR20180101411A (ko) | 전립선 비대증 치료를 위한 약제학적 조성물 | |
| US11123356B2 (en) | Methods of use for oenothein A and B from Epilobium species | |
| WO2004112766A1 (en) | Composition for lowering blood glucose | |
| JP2012520301A (ja) | エストロゲン化合物及びその使用方法 | |
| KR102628223B1 (ko) | 노르갈란타민을 포함하는 간 손상의 예방 또는 치료용 조성물 | |
| ES2745810T3 (es) | Composición que comprende una microalga enriquecida con silicio para una utilización terapéutica | |
| KR101351406B1 (ko) | 바우미 상황버섯 유래의 폴리페놀 추출물을 유효성분으로 함유하는 동맥경화 예방 및 치료용 조성물 | |
| WO2013012302A2 (fr) | Elaboration d'un sirop anti-inflammatoire/anti-œdemateux naturel a base d'extraits aqueux de plantes originaires du sud-est du maroc | |
| WO2007013824A1 (en) | Biologically active extracts from stephania brachyandra | |
| Agbortai et al. | Carbonated Herbal Alcoholic Beverage-Induced Hepatotoxicity in Wistar rats; Role of Aqueous Extracts of Stigma maydis | |
| JP2004194554A (ja) | 健康食品 | |
| US20200179426A1 (en) | Methods of use for oenothein a and b from epilobium species | |
| Kadannagari | Elucidate the Neuro-Pharmacodynamic Actions of 3-Hydroxypterostilbene | |
| Pal | Antioxidant potentials and pharmacological activities of marking nut (Semecarpus anacardium Lf) | |
| CN119969583A (zh) | 一种缓解抑郁的组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080709 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110128 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110906 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111124 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111226 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120313 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20120712 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120831 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120921 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140117 |